EGFR and lung carcinoma: In the case of lung cancer, the mutations are often found in the kinase domain [52], and inhibition of EGFR signaling by means of monoclonal antibodies and small molecule reversible TK inhibitors (TKIs) become a popular approach [12] that was overshadowed by a fast development of resistance.